Top of page

Experience

To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.

Filters

Vasta Platform $352.9 million IPO and Nasdaq listing

Davis Polk advised Vasta Platform Limited in connection with its SEC-registered initial public offering of an aggregate of 18,575,492 Class A common shares, at a price per Class A common…

Grupo Soma R$1.6 billion IPO

Davis Polk advised the joint bookrunners in connection with the initial public offering by Grupo de Moda SOMA S.A. and the selling shareholders of 163,636,363 common shares for an…

BioXcel Therapeutics $200 million stock offering

Davis Polk advised the underwriters in connection with the SEC-registered offering by BioXcel Therapeutics, Inc. of 4,000,000 shares of its common stock. The common stock is listed on the…

Innovent Biologics HK$4.65 billion share placement

Davis Polk advised the sole placing agent for the placement of 56,200,000 new shares and 36,800,000 existing shares in Innovent Biologics, Inc., for an aggregate consideration of…

Clarivate $6.8 billion combination with CPA Global

Davis Polk is advising Clarivate Plc on its approximately $6.8 billion combination with CPA Global. In the all-stock transaction, CPA Global shareholders will receive approximately 218…

Freeport-McMoRan $1.5 billion notes offering

Davis Polk advised Freeport-McMoRan Inc. (“FCX”) in connection with its SEC-registered offering of $1.5 billion of senior notes. The offering consisted of $650 million of 4.375% senior…
Back to top